Praxis Precision Medicines (PRAX) said Friday it received a recommendation from an independent data monitoring committee overseeing the company's study 1 of the Essential3 program of ulixacaltamide in essential tremor that the study be "stopped for futility."
The committee's decision was based on the possibility that the study will not meet its primary efficacy endpoint under the criteria set by the statistical model, the biopharmaceutical company added.
Praxis said that the committee also "encouraged" it to mull other analysis methods, adding that it intends to continue both study 1 and study 2 of the program and the results are expected in Q3.
Shares of the company fell 40% in recent Friday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.